nodes	percent_of_prediction	percent_of_DWPC	metapath
Desipramine—ORM1—Vismodegib—skin cancer	0.154	0.199	CbGbCtD
Desipramine—ORM1—Vemurafenib—skin cancer	0.122	0.157	CbGbCtD
Desipramine—SLC22A5—Dactinomycin—skin cancer	0.0701	0.0905	CbGbCtD
Desipramine—CYP1A2—Imiquimod—skin cancer	0.0559	0.0721	CbGbCtD
Desipramine—CYP2C19—Vismodegib—skin cancer	0.042	0.0542	CbGbCtD
Desipramine—CYP2E1—Dacarbazine—skin cancer	0.0406	0.0524	CbGbCtD
Desipramine—CYP2A6—Fluorouracil—skin cancer	0.0361	0.0465	CbGbCtD
Desipramine—ABCB1—Vismodegib—skin cancer	0.0339	0.0437	CbGbCtD
Desipramine—CYP1A2—Vemurafenib—skin cancer	0.0306	0.0395	CbGbCtD
Desipramine—CYP3A4—Imiquimod—skin cancer	0.0293	0.0378	CbGbCtD
Desipramine—CYP3A4—Temozolomide—skin cancer	0.0293	0.0378	CbGbCtD
Desipramine—CYP2D6—Vemurafenib—skin cancer	0.0252	0.0326	CbGbCtD
Desipramine—CYP1A2—Dacarbazine—skin cancer	0.0235	0.0303	CbGbCtD
Desipramine—CYP3A4—Vismodegib—skin cancer	0.0203	0.0262	CbGbCtD
Desipramine—ABCB1—Dactinomycin—skin cancer	0.0178	0.023	CbGbCtD
Desipramine—CYP3A4—Vemurafenib—skin cancer	0.016	0.0207	CbGbCtD
Desipramine—CYP1A2—Fluorouracil—skin cancer	0.0138	0.0178	CbGbCtD
Desipramine—ABCB1—Docetaxel—skin cancer	0.00919	0.0119	CbGbCtD
Desipramine—CYP3A4—Docetaxel—skin cancer	0.00551	0.0071	CbGbCtD
Desipramine—CHRM3—muscle of abdomen—skin cancer	0.00518	0.0829	CbGeAlD
Desipramine—HRH1—nose—skin cancer	0.004	0.064	CbGeAlD
Desipramine—CHRM5—skin epidermis—skin cancer	0.00339	0.0542	CbGeAlD
Desipramine—SLC6A3—nerve—skin cancer	0.00198	0.0316	CbGeAlD
Desipramine—SMPD1—connective tissue—skin cancer	0.00175	0.0279	CbGeAlD
Desipramine—SLC6A2—nerve—skin cancer	0.00159	0.0255	CbGeAlD
Desipramine—SMPD1—skin of body—skin cancer	0.00158	0.0252	CbGeAlD
Desipramine—HTR2A—hindlimb—skin cancer	0.00158	0.0252	CbGeAlD
Desipramine—DRD2—nerve—skin cancer	0.00145	0.0232	CbGeAlD
Desipramine—HTR2A—appendage—skin cancer	0.00135	0.0216	CbGeAlD
Desipramine—SMPD1—lymphoid tissue—skin cancer	0.00128	0.0204	CbGeAlD
Desipramine—SMPD1—female reproductive system—skin cancer	0.00123	0.0197	CbGeAlD
Desipramine—CYP2C18—mammalian vulva—skin cancer	0.00117	0.0187	CbGeAlD
Desipramine—SLC22A4—neck—skin cancer	0.00115	0.0184	CbGeAlD
Desipramine—CHRM5—epithelium—skin cancer	0.0011	0.0176	CbGeAlD
Desipramine—SLC22A3—nipple—skin cancer	0.00106	0.0169	CbGeAlD
Desipramine—CHRM5—skin of body—skin cancer	0.00105	0.0168	CbGeAlD
Desipramine—SMPD1—head—skin cancer	0.00103	0.0165	CbGeAlD
Desipramine—HTR2A—nerve—skin cancer	0.000958	0.0153	CbGeAlD
Desipramine—Fatigue—Vismodegib—skin cancer	0.00094	0.00674	CcSEcCtD
Desipramine—Constipation—Vismodegib—skin cancer	0.000932	0.00669	CcSEcCtD
Desipramine—Erectile dysfunction—Imiquimod—skin cancer	0.00093	0.00667	CcSEcCtD
Desipramine—Disorientation—Bleomycin—skin cancer	0.000928	0.00666	CcSEcCtD
Desipramine—Depression—Imiquimod—skin cancer	0.000898	0.00644	CcSEcCtD
Desipramine—Acute coronary syndrome—Imiquimod—skin cancer	0.000888	0.00637	CcSEcCtD
Desipramine—Myocardial infarction—Imiquimod—skin cancer	0.000883	0.00633	CcSEcCtD
Desipramine—Neuropathy peripheral—Imiquimod—skin cancer	0.000883	0.00633	CcSEcCtD
Desipramine—CHRM4—head—skin cancer	0.000876	0.014	CbGeAlD
Desipramine—Abdominal pain—Vismodegib—skin cancer	0.000862	0.00618	CcSEcCtD
Desipramine—Cerebrovascular accident—Bleomycin—skin cancer	0.000847	0.00608	CcSEcCtD
Desipramine—Alopecia—Vemurafenib—skin cancer	0.000838	0.00601	CcSEcCtD
Desipramine—HTR2A—endothelium—skin cancer	0.000816	0.013	CbGeAlD
Desipramine—Dysgeusia—Vemurafenib—skin cancer	0.000808	0.0058	CcSEcCtD
Desipramine—Blood alkaline phosphatase increased—Temozolomide—skin cancer	0.000805	0.00578	CcSEcCtD
Desipramine—Vascular purpura—Temozolomide—skin cancer	0.000783	0.00562	CcSEcCtD
Desipramine—Asthenia—Vismodegib—skin cancer	0.000782	0.00561	CcSEcCtD
Desipramine—Pruritus—Vismodegib—skin cancer	0.000771	0.00553	CcSEcCtD
Desipramine—SLC22A5—nipple—skin cancer	0.000768	0.0123	CbGeAlD
Desipramine—ADRB1—connective tissue—skin cancer	0.000755	0.0121	CbGeAlD
Desipramine—Tinnitus—Imiquimod—skin cancer	0.000754	0.00541	CcSEcCtD
Desipramine—HTR2A—blood vessel—skin cancer	0.000753	0.012	CbGeAlD
Desipramine—Flushing—Imiquimod—skin cancer	0.00075	0.00538	CcSEcCtD
Desipramine—SLC22A3—connective tissue—skin cancer	0.000749	0.012	CbGeAlD
Desipramine—Diarrhoea—Vismodegib—skin cancer	0.000746	0.00535	CcSEcCtD
Desipramine—Purpura—Temozolomide—skin cancer	0.000727	0.00521	CcSEcCtD
Desipramine—Arrhythmia—Imiquimod—skin cancer	0.000722	0.00518	CcSEcCtD
Desipramine—Disorientation—Fluorouracil—skin cancer	0.000721	0.00518	CcSEcCtD
Desipramine—SMPD1—lymph node—skin cancer	0.000721	0.0115	CbGeAlD
Desipramine—Liver function test abnormal—Dactinomycin—skin cancer	0.000715	0.00513	CcSEcCtD
Desipramine—Alopecia—Imiquimod—skin cancer	0.000714	0.00513	CcSEcCtD
Desipramine—CYP1A2—nipple—skin cancer	0.000696	0.0111	CbGeAlD
Desipramine—Vomiting—Vismodegib—skin cancer	0.000693	0.00497	CcSEcCtD
Desipramine—Rash—Vismodegib—skin cancer	0.000687	0.00493	CcSEcCtD
Desipramine—Dermatitis—Vismodegib—skin cancer	0.000687	0.00493	CcSEcCtD
Desipramine—CHRM5—head—skin cancer	0.000685	0.011	CbGeAlD
Desipramine—Ataxia—Temozolomide—skin cancer	0.000658	0.00473	CcSEcCtD
Desipramine—Ill-defined disorder—Imiquimod—skin cancer	0.000653	0.00469	CcSEcCtD
Desipramine—HRH1—nipple—skin cancer	0.000651	0.0104	CbGeAlD
Desipramine—Nausea—Vismodegib—skin cancer	0.000647	0.00465	CcSEcCtD
Desipramine—Agitation—Imiquimod—skin cancer	0.000647	0.00464	CcSEcCtD
Desipramine—Phosphatase alkaline increased—Docetaxel—skin cancer	0.000642	0.0046	CcSEcCtD
Desipramine—Malaise—Imiquimod—skin cancer	0.000635	0.00455	CcSEcCtD
Desipramine—Acute coronary syndrome—Bleomycin—skin cancer	0.000631	0.00453	CcSEcCtD
Desipramine—Hypotension—Vemurafenib—skin cancer	0.000629	0.00452	CcSEcCtD
Desipramine—Myocardial infarction—Bleomycin—skin cancer	0.000627	0.0045	CcSEcCtD
Desipramine—Stomatitis—Bleomycin—skin cancer	0.000624	0.00447	CcSEcCtD
Desipramine—Palpitations—Imiquimod—skin cancer	0.000622	0.00446	CcSEcCtD
Desipramine—SLC22A3—mammalian vulva—skin cancer	0.000617	0.00986	CbGeAlD
Desipramine—Convulsion—Imiquimod—skin cancer	0.00061	0.00438	CcSEcCtD
Desipramine—Hypertension—Imiquimod—skin cancer	0.000608	0.00436	CcSEcCtD
Desipramine—Ataxia—Fluorouracil—skin cancer	0.000607	0.00435	CcSEcCtD
Desipramine—ORM1—female reproductive system—skin cancer	0.000604	0.00965	CbGeAlD
Desipramine—Anxiety—Imiquimod—skin cancer	0.000597	0.00428	CcSEcCtD
Desipramine—Discomfort—Imiquimod—skin cancer	0.000592	0.00425	CcSEcCtD
Desipramine—Dry mouth—Imiquimod—skin cancer	0.000586	0.0042	CcSEcCtD
Desipramine—Decreased appetite—Vemurafenib—skin cancer	0.000585	0.0042	CcSEcCtD
Desipramine—Stomatitis—Dactinomycin—skin cancer	0.000582	0.00417	CcSEcCtD
Desipramine—Fatigue—Vemurafenib—skin cancer	0.000581	0.00417	CcSEcCtD
Desipramine—SLC22A4—female reproductive system—skin cancer	0.000581	0.00928	CbGeAlD
Desipramine—Constipation—Vemurafenib—skin cancer	0.000576	0.00413	CcSEcCtD
Desipramine—Oedema—Imiquimod—skin cancer	0.000574	0.00412	CcSEcCtD
Desipramine—Lightheadedness—Docetaxel—skin cancer	0.000574	0.00412	CcSEcCtD
Desipramine—Hypoaesthesia—Bleomycin—skin cancer	0.000571	0.0041	CcSEcCtD
Desipramine—Tachycardia—Imiquimod—skin cancer	0.000561	0.00402	CcSEcCtD
Desipramine—Pollakiuria—Temozolomide—skin cancer	0.000559	0.00401	CcSEcCtD
Desipramine—Erectile dysfunction—Temozolomide—skin cancer	0.000557	0.004	CcSEcCtD
Desipramine—Agranulocytosis—Dactinomycin—skin cancer	0.000557	0.004	CcSEcCtD
Desipramine—Eosinophilia—Fluorouracil—skin cancer	0.000552	0.00396	CcSEcCtD
Desipramine—Weight increased—Temozolomide—skin cancer	0.000551	0.00395	CcSEcCtD
Desipramine—Anorexia—Imiquimod—skin cancer	0.000547	0.00393	CcSEcCtD
Desipramine—HTR2C—female reproductive system—skin cancer	0.000543	0.00867	CbGeAlD
Desipramine—HTR2A—neck—skin cancer	0.000538	0.00861	CbGeAlD
Desipramine—Depression—Temozolomide—skin cancer	0.000538	0.00386	CcSEcCtD
Desipramine—Hepatitis—Dactinomycin—skin cancer	0.000536	0.00384	CcSEcCtD
Desipramine—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.000535	0.00384	CcSEcCtD
Desipramine—Flushing—Bleomycin—skin cancer	0.000533	0.00382	CcSEcCtD
Desipramine—Body temperature increased—Vemurafenib—skin cancer	0.000532	0.00382	CcSEcCtD
Desipramine—ADRB1—female reproductive system—skin cancer	0.000532	0.00851	CbGeAlD
Desipramine—Neuropathy peripheral—Temozolomide—skin cancer	0.000529	0.0038	CcSEcCtD
Desipramine—SLC22A3—female reproductive system—skin cancer	0.000528	0.00845	CbGeAlD
Desipramine—Stomatitis—Temozolomide—skin cancer	0.000526	0.00377	CcSEcCtD
Desipramine—Insomnia—Imiquimod—skin cancer	0.000519	0.00373	CcSEcCtD
Desipramine—Paraesthesia—Imiquimod—skin cancer	0.000516	0.0037	CcSEcCtD
Desipramine—SLC6A4—female reproductive system—skin cancer	0.000514	0.00822	CbGeAlD
Desipramine—CHRM1—female reproductive system—skin cancer	0.000512	0.00819	CbGeAlD
Desipramine—Somnolence—Imiquimod—skin cancer	0.000511	0.00366	CcSEcCtD
Desipramine—Alopecia—Bleomycin—skin cancer	0.000507	0.00364	CcSEcCtD
Desipramine—Dyspepsia—Imiquimod—skin cancer	0.000506	0.00363	CcSEcCtD
Desipramine—Decreased appetite—Imiquimod—skin cancer	0.000499	0.00358	CcSEcCtD
Desipramine—Flushing—Dactinomycin—skin cancer	0.000497	0.00357	CcSEcCtD
Desipramine—Fatigue—Imiquimod—skin cancer	0.000495	0.00355	CcSEcCtD
Desipramine—ABCB1—blood vessel—skin cancer	0.000493	0.00788	CbGeAlD
Desipramine—SLC22A5—skin of body—skin cancer	0.000492	0.00786	CbGeAlD
Desipramine—Acute coronary syndrome—Fluorouracil—skin cancer	0.00049	0.00352	CcSEcCtD
Desipramine—Neuropathy peripheral—Fluorouracil—skin cancer	0.000487	0.0035	CcSEcCtD
Desipramine—Myocardial infarction—Fluorouracil—skin cancer	0.000487	0.0035	CcSEcCtD
Desipramine—Stomatitis—Fluorouracil—skin cancer	0.000485	0.00348	CcSEcCtD
Desipramine—Hepatitis—Temozolomide—skin cancer	0.000484	0.00348	CcSEcCtD
Desipramine—Asthenia—Vemurafenib—skin cancer	0.000483	0.00347	CcSEcCtD
Desipramine—Hallucination—Temozolomide—skin cancer	0.000482	0.00346	CcSEcCtD
Desipramine—Hypoaesthesia—Temozolomide—skin cancer	0.000482	0.00346	CcSEcCtD
Desipramine—Pruritus—Vemurafenib—skin cancer	0.000476	0.00342	CcSEcCtD
Desipramine—Alopecia—Dactinomycin—skin cancer	0.000473	0.0034	CcSEcCtD
Desipramine—Feeling abnormal—Imiquimod—skin cancer	0.000473	0.0034	CcSEcCtD
Desipramine—CHRM2—head—skin cancer	0.00047	0.00752	CbGeAlD
Desipramine—SLC6A3—head—skin cancer	0.000469	0.0075	CbGeAlD
Desipramine—Agranulocytosis—Fluorouracil—skin cancer	0.000464	0.00333	CcSEcCtD
Desipramine—Ill-defined disorder—Bleomycin—skin cancer	0.000464	0.00333	CcSEcCtD
Desipramine—HRH1—connective tissue—skin cancer	0.000462	0.00739	CbGeAlD
Desipramine—SLC22A1—head—skin cancer	0.000462	0.00738	CbGeAlD
Desipramine—Diarrhoea—Vemurafenib—skin cancer	0.000461	0.00331	CcSEcCtD
Desipramine—CHRM3—female reproductive system—skin cancer	0.000458	0.00733	CbGeAlD
Desipramine—Urticaria—Imiquimod—skin cancer	0.000456	0.00327	CcSEcCtD
Desipramine—Abdominal pain—Imiquimod—skin cancer	0.000454	0.00326	CcSEcCtD
Desipramine—Body temperature increased—Imiquimod—skin cancer	0.000454	0.00326	CcSEcCtD
Desipramine—HTR2C—head—skin cancer	0.000453	0.00725	CbGeAlD
Desipramine—SLC6A2—female reproductive system—skin cancer	0.000453	0.00724	CbGeAlD
Desipramine—Tinnitus—Temozolomide—skin cancer	0.000452	0.00324	CcSEcCtD
Desipramine—Malaise—Bleomycin—skin cancer	0.000451	0.00324	CcSEcCtD
Desipramine—Flushing—Temozolomide—skin cancer	0.00045	0.00323	CcSEcCtD
Desipramine—Dizziness—Vemurafenib—skin cancer	0.000445	0.0032	CcSEcCtD
Desipramine—ADRB1—head—skin cancer	0.000445	0.00711	CbGeAlD
Desipramine—Hypoaesthesia—Fluorouracil—skin cancer	0.000444	0.00319	CcSEcCtD
Desipramine—SLC22A3—head—skin cancer	0.000441	0.00706	CbGeAlD
Desipramine—HRH1—epithelium—skin cancer	0.000439	0.00701	CbGeAlD
Desipramine—Ataxia—Docetaxel—skin cancer	0.000438	0.00314	CcSEcCtD
Desipramine—Ill-defined disorder—Dactinomycin—skin cancer	0.000433	0.0031	CcSEcCtD
Desipramine—Liver function test abnormal—Docetaxel—skin cancer	0.00043	0.00309	CcSEcCtD
Desipramine—SLC6A4—head—skin cancer	0.00043	0.00687	CbGeAlD
Desipramine—Vomiting—Vemurafenib—skin cancer	0.000428	0.00307	CcSEcCtD
Desipramine—Alopecia—Temozolomide—skin cancer	0.000428	0.00307	CcSEcCtD
Desipramine—CHRM1—head—skin cancer	0.000428	0.00684	CbGeAlD
Desipramine—CYP2B6—skin of body—skin cancer	0.000427	0.00683	CbGeAlD
Desipramine—Rash—Vemurafenib—skin cancer	0.000425	0.00305	CcSEcCtD
Desipramine—Dermatitis—Vemurafenib—skin cancer	0.000424	0.00304	CcSEcCtD
Desipramine—Headache—Vemurafenib—skin cancer	0.000422	0.00303	CcSEcCtD
Desipramine—Discomfort—Bleomycin—skin cancer	0.000421	0.00302	CcSEcCtD
Desipramine—Malaise—Dactinomycin—skin cancer	0.00042	0.00302	CcSEcCtD
Desipramine—Dysgeusia—Temozolomide—skin cancer	0.000413	0.00296	CcSEcCtD
Desipramine—Asthenia—Imiquimod—skin cancer	0.000412	0.00296	CcSEcCtD
Desipramine—Confusional state—Bleomycin—skin cancer	0.000411	0.00295	CcSEcCtD
Desipramine—Oedema—Bleomycin—skin cancer	0.000408	0.00293	CcSEcCtD
Desipramine—Pruritus—Imiquimod—skin cancer	0.000406	0.00292	CcSEcCtD
Desipramine—Nausea—Vemurafenib—skin cancer	0.0004	0.00287	CcSEcCtD
Desipramine—Thrombocytopenia—Bleomycin—skin cancer	0.000399	0.00287	CcSEcCtD
Desipramine—Arrhythmia—Fluorouracil—skin cancer	0.000399	0.00286	CcSEcCtD
Desipramine—Vision blurred—Temozolomide—skin cancer	0.000397	0.00285	CcSEcCtD
Desipramine—Tremor—Temozolomide—skin cancer	0.000395	0.00284	CcSEcCtD
Desipramine—Alopecia—Fluorouracil—skin cancer	0.000394	0.00283	CcSEcCtD
Desipramine—Diarrhoea—Imiquimod—skin cancer	0.000393	0.00282	CcSEcCtD
Desipramine—Discomfort—Dactinomycin—skin cancer	0.000392	0.00281	CcSEcCtD
Desipramine—Ill-defined disorder—Temozolomide—skin cancer	0.000391	0.00281	CcSEcCtD
Desipramine—Anorexia—Bleomycin—skin cancer	0.000389	0.00279	CcSEcCtD
Desipramine—Agitation—Temozolomide—skin cancer	0.000388	0.00278	CcSEcCtD
Desipramine—HTR2A—connective tissue—skin cancer	0.000386	0.00617	CbGeAlD
Desipramine—SLC22A5—female reproductive system—skin cancer	0.000384	0.00614	CbGeAlD
Desipramine—CHRM3—head—skin cancer	0.000383	0.00612	CbGeAlD
Desipramine—HTR1A—head—skin cancer	0.000381	0.0061	CbGeAlD
Desipramine—Hypotension—Bleomycin—skin cancer	0.000381	0.00274	CcSEcCtD
Desipramine—Oedema—Dactinomycin—skin cancer	0.000381	0.00273	CcSEcCtD
Desipramine—HRH1—mammalian vulva—skin cancer	0.00038	0.00608	CbGeAlD
Desipramine—Malaise—Temozolomide—skin cancer	0.00038	0.00273	CcSEcCtD
Desipramine—Dizziness—Imiquimod—skin cancer	0.00038	0.00273	CcSEcCtD
Desipramine—SLC6A2—head—skin cancer	0.000378	0.00605	CbGeAlD
Desipramine—Palpitations—Temozolomide—skin cancer	0.000373	0.00267	CcSEcCtD
Desipramine—Thrombocytopenia—Dactinomycin—skin cancer	0.000373	0.00267	CcSEcCtD
Desipramine—Paraesthesia—Bleomycin—skin cancer	0.000366	0.00263	CcSEcCtD
Desipramine—HTR2A—epithelium—skin cancer	0.000366	0.00586	CbGeAlD
Desipramine—Weight increased—Docetaxel—skin cancer	0.000366	0.00263	CcSEcCtD
Desipramine—Vision blurred—Fluorouracil—skin cancer	0.000366	0.00263	CcSEcCtD
Desipramine—Convulsion—Temozolomide—skin cancer	0.000365	0.00262	CcSEcCtD
Desipramine—Vomiting—Imiquimod—skin cancer	0.000365	0.00262	CcSEcCtD
Desipramine—Hypertension—Temozolomide—skin cancer	0.000364	0.00261	CcSEcCtD
Desipramine—Anorexia—Dactinomycin—skin cancer	0.000363	0.0026	CcSEcCtD
Desipramine—Rash—Imiquimod—skin cancer	0.000362	0.0026	CcSEcCtD
Desipramine—Dermatitis—Imiquimod—skin cancer	0.000362	0.0026	CcSEcCtD
Desipramine—Headache—Imiquimod—skin cancer	0.00036	0.00258	CcSEcCtD
Desipramine—Anxiety—Temozolomide—skin cancer	0.000358	0.00257	CcSEcCtD
Desipramine—Discomfort—Temozolomide—skin cancer	0.000355	0.00255	CcSEcCtD
Desipramine—Decreased appetite—Bleomycin—skin cancer	0.000355	0.00255	CcSEcCtD
Desipramine—Acute coronary syndrome—Docetaxel—skin cancer	0.000354	0.00254	CcSEcCtD
Desipramine—ORM1—lymph node—skin cancer	0.000353	0.00564	CbGeAlD
Desipramine—Neuropathy peripheral—Docetaxel—skin cancer	0.000352	0.00252	CcSEcCtD
Desipramine—Myocardial infarction—Docetaxel—skin cancer	0.000352	0.00252	CcSEcCtD
Desipramine—Dry mouth—Temozolomide—skin cancer	0.000351	0.00252	CcSEcCtD
Desipramine—Jaundice—Docetaxel—skin cancer	0.00035	0.00251	CcSEcCtD
Desipramine—Stomatitis—Docetaxel—skin cancer	0.00035	0.00251	CcSEcCtD
Desipramine—Confusional state—Temozolomide—skin cancer	0.000347	0.00249	CcSEcCtD
Desipramine—CYP2B6—lymphoid tissue—skin cancer	0.000346	0.00553	CbGeAlD
Desipramine—DRD2—head—skin cancer	0.000345	0.00551	CbGeAlD
Desipramine—Oedema—Temozolomide—skin cancer	0.000344	0.00247	CcSEcCtD
Desipramine—Nausea—Imiquimod—skin cancer	0.000341	0.00245	CcSEcCtD
Desipramine—SLC22A4—lymph node—skin cancer	0.00034	0.00543	CbGeAlD
Desipramine—Thrombocytopenia—Temozolomide—skin cancer	0.000337	0.00242	CcSEcCtD
Desipramine—Convulsion—Fluorouracil—skin cancer	0.000337	0.00242	CcSEcCtD
Desipramine—Feeling abnormal—Bleomycin—skin cancer	0.000336	0.00241	CcSEcCtD
Desipramine—Agranulocytosis—Docetaxel—skin cancer	0.000335	0.0024	CcSEcCtD
Desipramine—CYP2B6—female reproductive system—skin cancer	0.000334	0.00533	CbGeAlD
Desipramine—Decreased appetite—Dactinomycin—skin cancer	0.000331	0.00237	CcSEcCtD
Desipramine—Fatigue—Dactinomycin—skin cancer	0.000328	0.00235	CcSEcCtD
Desipramine—Anorexia—Temozolomide—skin cancer	0.000328	0.00235	CcSEcCtD
Desipramine—Discomfort—Fluorouracil—skin cancer	0.000327	0.00235	CcSEcCtD
Desipramine—HRH1—female reproductive system—skin cancer	0.000326	0.00521	CbGeAlD
Desipramine—CYP2E1—lymphoid tissue—skin cancer	0.000325	0.00519	CbGeAlD
Desipramine—Urticaria—Bleomycin—skin cancer	0.000324	0.00233	CcSEcCtD
Desipramine—Body temperature increased—Bleomycin—skin cancer	0.000323	0.00231	CcSEcCtD
Desipramine—Hepatitis—Docetaxel—skin cancer	0.000322	0.00231	CcSEcCtD
Desipramine—Hypoaesthesia—Docetaxel—skin cancer	0.000321	0.0023	CcSEcCtD
Desipramine—Confusional state—Fluorouracil—skin cancer	0.00032	0.00229	CcSEcCtD
Desipramine—Oedema—Fluorouracil—skin cancer	0.000317	0.00228	CcSEcCtD
Desipramine—Feeling abnormal—Dactinomycin—skin cancer	0.000314	0.00225	CcSEcCtD
Desipramine—CYP2E1—female reproductive system—skin cancer	0.000313	0.00501	CbGeAlD
Desipramine—Insomnia—Temozolomide—skin cancer	0.000311	0.00223	CcSEcCtD
Desipramine—Thrombocytopenia—Fluorouracil—skin cancer	0.00031	0.00223	CcSEcCtD
Desipramine—Tachycardia—Fluorouracil—skin cancer	0.00031	0.00222	CcSEcCtD
Desipramine—SLC22A3—lymph node—skin cancer	0.000309	0.00494	CbGeAlD
Desipramine—Paraesthesia—Temozolomide—skin cancer	0.000309	0.00222	CcSEcCtD
Desipramine—Somnolence—Temozolomide—skin cancer	0.000306	0.0022	CcSEcCtD
Desipramine—Dyspepsia—Temozolomide—skin cancer	0.000303	0.00217	CcSEcCtD
Desipramine—Anorexia—Fluorouracil—skin cancer	0.000302	0.00217	CcSEcCtD
Desipramine—Abdominal pain—Dactinomycin—skin cancer	0.000301	0.00216	CcSEcCtD
Desipramine—Body temperature increased—Dactinomycin—skin cancer	0.000301	0.00216	CcSEcCtD
Desipramine—Decreased appetite—Temozolomide—skin cancer	0.000299	0.00215	CcSEcCtD
Desipramine—Flushing—Docetaxel—skin cancer	0.000299	0.00215	CcSEcCtD
Desipramine—Fatigue—Temozolomide—skin cancer	0.000297	0.00213	CcSEcCtD
Desipramine—Hypotension—Fluorouracil—skin cancer	0.000296	0.00213	CcSEcCtD
Desipramine—Constipation—Temozolomide—skin cancer	0.000294	0.00211	CcSEcCtD
Desipramine—Asthenia—Bleomycin—skin cancer	0.000293	0.0021	CcSEcCtD
Desipramine—Pruritus—Bleomycin—skin cancer	0.000289	0.00207	CcSEcCtD
Desipramine—Arrhythmia—Docetaxel—skin cancer	0.000288	0.00207	CcSEcCtD
Desipramine—Insomnia—Fluorouracil—skin cancer	0.000287	0.00206	CcSEcCtD
Desipramine—Paraesthesia—Fluorouracil—skin cancer	0.000285	0.00204	CcSEcCtD
Desipramine—Alopecia—Docetaxel—skin cancer	0.000285	0.00204	CcSEcCtD
Desipramine—Feeling abnormal—Temozolomide—skin cancer	0.000284	0.00204	CcSEcCtD
Desipramine—Somnolence—Fluorouracil—skin cancer	0.000282	0.00202	CcSEcCtD
Desipramine—Dyspepsia—Fluorouracil—skin cancer	0.000279	0.002	CcSEcCtD
Desipramine—CYP2B6—head—skin cancer	0.000279	0.00446	CbGeAlD
Desipramine—Decreased appetite—Fluorouracil—skin cancer	0.000276	0.00198	CcSEcCtD
Desipramine—Dysgeusia—Docetaxel—skin cancer	0.000275	0.00197	CcSEcCtD
Desipramine—Urticaria—Temozolomide—skin cancer	0.000273	0.00196	CcSEcCtD
Desipramine—Asthenia—Dactinomycin—skin cancer	0.000273	0.00196	CcSEcCtD
Desipramine—HRH1—head—skin cancer	0.000272	0.00435	CbGeAlD
Desipramine—HTR2A—female reproductive system—skin cancer	0.000272	0.00435	CbGeAlD
Desipramine—Body temperature increased—Temozolomide—skin cancer	0.000272	0.00195	CcSEcCtD
Desipramine—Abdominal pain—Temozolomide—skin cancer	0.000272	0.00195	CcSEcCtD
Desipramine—SLC6A2—lymph node—skin cancer	0.000265	0.00423	CbGeAlD
Desipramine—CYP2E1—head—skin cancer	0.000262	0.00418	CbGeAlD
Desipramine—Feeling abnormal—Fluorouracil—skin cancer	0.000261	0.00188	CcSEcCtD
Desipramine—Diarrhoea—Dactinomycin—skin cancer	0.00026	0.00187	CcSEcCtD
Desipramine—Vomiting—Bleomycin—skin cancer	0.000259	0.00186	CcSEcCtD
Desipramine—Rash—Bleomycin—skin cancer	0.000257	0.00185	CcSEcCtD
Desipramine—Dermatitis—Bleomycin—skin cancer	0.000257	0.00184	CcSEcCtD
Desipramine—CYP3A4—female reproductive system—skin cancer	0.000252	0.00403	CbGeAlD
Desipramine—Urticaria—Fluorouracil—skin cancer	0.000252	0.00181	CcSEcCtD
Desipramine—Body temperature increased—Fluorouracil—skin cancer	0.000251	0.0018	CcSEcCtD
Desipramine—CYP2D6—female reproductive system—skin cancer	0.000248	0.00396	CbGeAlD
Desipramine—Palpitations—Docetaxel—skin cancer	0.000248	0.00178	CcSEcCtD
Desipramine—Asthenia—Temozolomide—skin cancer	0.000247	0.00177	CcSEcCtD
Desipramine—Pruritus—Temozolomide—skin cancer	0.000244	0.00175	CcSEcCtD
Desipramine—Convulsion—Docetaxel—skin cancer	0.000243	0.00174	CcSEcCtD
Desipramine—Nausea—Bleomycin—skin cancer	0.000242	0.00174	CcSEcCtD
Desipramine—Hypertension—Docetaxel—skin cancer	0.000242	0.00174	CcSEcCtD
Desipramine—Vomiting—Dactinomycin—skin cancer	0.000242	0.00174	CcSEcCtD
Desipramine—ABCB1—epithelium—skin cancer	0.00024	0.00384	CbGeAlD
Desipramine—Rash—Dactinomycin—skin cancer	0.00024	0.00172	CcSEcCtD
Desipramine—Diarrhoea—Temozolomide—skin cancer	0.000235	0.00169	CcSEcCtD
Desipramine—Dry mouth—Docetaxel—skin cancer	0.000234	0.00168	CcSEcCtD
Desipramine—Confusional state—Docetaxel—skin cancer	0.000231	0.00166	CcSEcCtD
Desipramine—Oedema—Docetaxel—skin cancer	0.000229	0.00164	CcSEcCtD
Desipramine—Dizziness—Temozolomide—skin cancer	0.000228	0.00163	CcSEcCtD
Desipramine—HTR2A—head—skin cancer	0.000227	0.00363	CbGeAlD
Desipramine—Nausea—Dactinomycin—skin cancer	0.000226	0.00162	CcSEcCtD
Desipramine—SLC22A5—lymph node—skin cancer	0.000225	0.00359	CbGeAlD
Desipramine—Pruritus—Fluorouracil—skin cancer	0.000224	0.00161	CcSEcCtD
Desipramine—Thrombocytopenia—Docetaxel—skin cancer	0.000224	0.00161	CcSEcCtD
Desipramine—Tachycardia—Docetaxel—skin cancer	0.000223	0.0016	CcSEcCtD
Desipramine—Vomiting—Temozolomide—skin cancer	0.000219	0.00157	CcSEcCtD
Desipramine—Anorexia—Docetaxel—skin cancer	0.000218	0.00157	CcSEcCtD
Desipramine—Rash—Temozolomide—skin cancer	0.000217	0.00156	CcSEcCtD
Desipramine—Diarrhoea—Fluorouracil—skin cancer	0.000217	0.00156	CcSEcCtD
Desipramine—Dermatitis—Temozolomide—skin cancer	0.000217	0.00156	CcSEcCtD
Desipramine—Headache—Temozolomide—skin cancer	0.000216	0.00155	CcSEcCtD
Desipramine—Hypotension—Docetaxel—skin cancer	0.000214	0.00153	CcSEcCtD
Desipramine—Dizziness—Fluorouracil—skin cancer	0.00021	0.0015	CcSEcCtD
Desipramine—ABCB1—mammalian vulva—skin cancer	0.000208	0.00333	CbGeAlD
Desipramine—CYP2D6—head—skin cancer	0.000207	0.00331	CbGeAlD
Desipramine—Insomnia—Docetaxel—skin cancer	0.000207	0.00149	CcSEcCtD
Desipramine—Paraesthesia—Docetaxel—skin cancer	0.000206	0.00147	CcSEcCtD
Desipramine—Nausea—Temozolomide—skin cancer	0.000204	0.00147	CcSEcCtD
Desipramine—Somnolence—Docetaxel—skin cancer	0.000203	0.00146	CcSEcCtD
Desipramine—Vomiting—Fluorouracil—skin cancer	0.000202	0.00145	CcSEcCtD
Desipramine—Dyspepsia—Docetaxel—skin cancer	0.000201	0.00145	CcSEcCtD
Desipramine—Rash—Fluorouracil—skin cancer	0.0002	0.00143	CcSEcCtD
Desipramine—Dermatitis—Fluorouracil—skin cancer	0.0002	0.00143	CcSEcCtD
Desipramine—Decreased appetite—Docetaxel—skin cancer	0.000199	0.00143	CcSEcCtD
Desipramine—Headache—Fluorouracil—skin cancer	0.000199	0.00143	CcSEcCtD
Desipramine—Fatigue—Docetaxel—skin cancer	0.000197	0.00142	CcSEcCtD
Desipramine—Constipation—Docetaxel—skin cancer	0.000196	0.0014	CcSEcCtD
Desipramine—HRH1—lymph node—skin cancer	0.000191	0.00305	CbGeAlD
Desipramine—Feeling abnormal—Docetaxel—skin cancer	0.000189	0.00135	CcSEcCtD
Desipramine—Nausea—Fluorouracil—skin cancer	0.000188	0.00135	CcSEcCtD
Desipramine—ABCB1—lymphoid tissue—skin cancer	0.000185	0.00296	CbGeAlD
Desipramine—Body temperature increased—Docetaxel—skin cancer	0.000181	0.0013	CcSEcCtD
Desipramine—Abdominal pain—Docetaxel—skin cancer	0.000181	0.0013	CcSEcCtD
Desipramine—ABCB1—female reproductive system—skin cancer	0.000178	0.00285	CbGeAlD
Desipramine—Asthenia—Docetaxel—skin cancer	0.000164	0.00118	CcSEcCtD
Desipramine—Pruritus—Docetaxel—skin cancer	0.000162	0.00116	CcSEcCtD
Desipramine—Diarrhoea—Docetaxel—skin cancer	0.000157	0.00112	CcSEcCtD
Desipramine—Dizziness—Docetaxel—skin cancer	0.000151	0.00109	CcSEcCtD
Desipramine—ABCB1—head—skin cancer	0.000149	0.00238	CbGeAlD
Desipramine—Vomiting—Docetaxel—skin cancer	0.000146	0.00104	CcSEcCtD
Desipramine—Rash—Docetaxel—skin cancer	0.000144	0.00104	CcSEcCtD
Desipramine—Dermatitis—Docetaxel—skin cancer	0.000144	0.00103	CcSEcCtD
Desipramine—Headache—Docetaxel—skin cancer	0.000143	0.00103	CcSEcCtD
Desipramine—Nausea—Docetaxel—skin cancer	0.000136	0.000976	CcSEcCtD
Desipramine—ABCB1—lymph node—skin cancer	0.000104	0.00167	CbGeAlD
Desipramine—CYP2C18—Metabolism—ERCC2—skin cancer	1.13e-05	0.000486	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—RASA1—skin cancer	1.13e-05	0.000485	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—FOXO4—skin cancer	1.13e-05	0.000485	CbGpPWpGaD
Desipramine—SLC6A3—Neuronal System—HRAS—skin cancer	1.12e-05	0.000481	CbGpPWpGaD
Desipramine—DRD2—Circadian rythm related genes—IL6—skin cancer	1.12e-05	0.000481	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—ENO2—skin cancer	1.11e-05	0.000479	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—SHH—skin cancer	1.11e-05	0.000478	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—RASA1—skin cancer	1.1e-05	0.000475	CbGpPWpGaD
Desipramine—CHRM1—Circadian rythm related genes—IL6—skin cancer	1.09e-05	0.00047	CbGpPWpGaD
Desipramine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.09e-05	0.000468	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—SHH—skin cancer	1.09e-05	0.000467	CbGpPWpGaD
Desipramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.08e-05	0.000467	CbGpPWpGaD
Desipramine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.08e-05	0.000466	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—SHH—skin cancer	1.08e-05	0.000465	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—FOXO4—skin cancer	1.08e-05	0.000465	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—RASA1—skin cancer	1.08e-05	0.000464	CbGpPWpGaD
Desipramine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.08e-05	0.000464	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—SMO—skin cancer	1.08e-05	0.000463	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—PTCH1—skin cancer	1.08e-05	0.000463	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—RASA1—skin cancer	1.07e-05	0.000462	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—CSPG4—skin cancer	1.06e-05	0.000458	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—PTCH1—skin cancer	1.05e-05	0.000453	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—SMO—skin cancer	1.05e-05	0.000453	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—PTGER4—skin cancer	1.05e-05	0.000451	CbGpPWpGaD
Desipramine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.04e-05	0.000448	CbGpPWpGaD
Desipramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.04e-05	0.000447	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—CSPG4—skin cancer	1.04e-05	0.000447	CbGpPWpGaD
Desipramine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.04e-05	0.000446	CbGpPWpGaD
Desipramine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.03e-05	0.000444	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—SMO—skin cancer	1.03e-05	0.000443	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—PTCH1—skin cancer	1.03e-05	0.000443	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PLIN2—skin cancer	1.03e-05	0.000442	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—PTGER4—skin cancer	1.02e-05	0.000441	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—PTCH1—skin cancer	1.02e-05	0.000441	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—SMO—skin cancer	1.02e-05	0.000441	CbGpPWpGaD
Desipramine—SLC22A2—Neuronal System—HRAS—skin cancer	1.02e-05	0.000438	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—PTGER4—skin cancer	1e-05	0.000431	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—PTGER4—skin cancer	9.96e-06	0.000429	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—CSPG4—skin cancer	9.78e-06	0.000421	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—ENO2—skin cancer	9.56e-06	0.000412	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—SHH—skin cancer	9.53e-06	0.00041	CbGpPWpGaD
Desipramine—SLC22A1—Neuronal System—HRAS—skin cancer	9.47e-06	0.000408	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—RASA1—skin cancer	9.47e-06	0.000408	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—SHH—skin cancer	9.37e-06	0.000404	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—ENO2—skin cancer	9.37e-06	0.000403	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—SHH—skin cancer	9.35e-06	0.000403	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—SHH—skin cancer	9.32e-06	0.000401	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—RASA1—skin cancer	9.32e-06	0.000401	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—RASA1—skin cancer	9.3e-06	0.0004	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—SHH—skin cancer	9.29e-06	0.0004	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—RASA1—skin cancer	9.27e-06	0.000399	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—FOXO4—skin cancer	9.25e-06	0.000398	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—RASA1—skin cancer	9.24e-06	0.000398	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—SHH—skin cancer	9.2e-06	0.000396	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—RASA1—skin cancer	9.15e-06	0.000394	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—FOXO4—skin cancer	9.05e-06	0.00039	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—PTCH1—skin cancer	9.03e-06	0.000389	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—SMO—skin cancer	9.03e-06	0.000389	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—PTCH1—skin cancer	8.89e-06	0.000383	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—SMO—skin cancer	8.89e-06	0.000383	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—PTCH1—skin cancer	8.87e-06	0.000382	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—SMO—skin cancer	8.87e-06	0.000382	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—FOXO4—skin cancer	8.85e-06	0.000381	CbGpPWpGaD
Desipramine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	8.85e-06	0.000381	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—SMO—skin cancer	8.84e-06	0.000381	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—PTCH1—skin cancer	8.84e-06	0.000381	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—PTCH1—skin cancer	8.81e-06	0.000379	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—SMO—skin cancer	8.81e-06	0.000379	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—FOXO4—skin cancer	8.8e-06	0.000379	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—PTGER4—skin cancer	8.79e-06	0.000379	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—PTCH1—skin cancer	8.73e-06	0.000376	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—SMO—skin cancer	8.73e-06	0.000376	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—PTGER4—skin cancer	8.65e-06	0.000373	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—PTGER4—skin cancer	8.63e-06	0.000372	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—PTGER4—skin cancer	8.61e-06	0.000371	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—PTGER4—skin cancer	8.58e-06	0.000369	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—PTGER4—skin cancer	8.49e-06	0.000366	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—CSPG4—skin cancer	8.28e-06	0.000357	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PLIN2—skin cancer	7.93e-06	0.000341	CbGpPWpGaD
Desipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	7.86e-06	0.000339	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—FOXO4—skin cancer	7.77e-06	0.000334	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—FOXO4—skin cancer	7.64e-06	0.000329	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—FOXO4—skin cancer	7.63e-06	0.000328	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—FOXO4—skin cancer	7.6e-06	0.000327	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—FOXO4—skin cancer	7.58e-06	0.000326	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—TERT—skin cancer	7.53e-06	0.000324	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—FOXO4—skin cancer	7.5e-06	0.000323	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—ERCC2—skin cancer	7.5e-06	0.000323	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—ENO2—skin cancer	7.23e-06	0.000311	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—TERT—skin cancer	7.21e-06	0.00031	CbGpPWpGaD
Desipramine—SLC22A3—Metabolism—PTGS2—skin cancer	7.17e-06	0.000309	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—ENO2—skin cancer	7.05e-06	0.000304	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—ERCC2—skin cancer	6.99e-06	0.000301	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—ERCC2—skin cancer	6.88e-06	0.000296	CbGpPWpGaD
Desipramine—CYP2C18—Metabolism—PTGS2—skin cancer	6.77e-06	0.000292	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—ENO2—skin cancer	6.65e-06	0.000286	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—ERCC2—skin cancer	6.46e-06	0.000278	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—CSPG4—skin cancer	6.39e-06	0.000275	CbGpPWpGaD
Desipramine—CHRM4—Signaling by GPCR—NRAS—skin cancer	6.34e-06	0.000273	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—TERT—skin cancer	6.18e-06	0.000266	CbGpPWpGaD
Desipramine—CHRM5—Signaling by GPCR—NRAS—skin cancer	6.08e-06	0.000262	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—TERT—skin cancer	6.04e-06	0.00026	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—BRAF—skin cancer	5.96e-06	0.000257	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—TERT—skin cancer	5.91e-06	0.000254	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—TERT—skin cancer	5.88e-06	0.000253	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—BRAF—skin cancer	5.71e-06	0.000246	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.65e-06	0.000243	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—ENO2—skin cancer	5.63e-06	0.000242	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—ERCC2—skin cancer	5.55e-06	0.000239	CbGpPWpGaD
Desipramine—CHRM4—Signaling by GPCR—KRAS—skin cancer	5.46e-06	0.000235	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—ERCC2—skin cancer	5.44e-06	0.000234	CbGpPWpGaD
Desipramine—CHRM5—Signaling by GPCR—KRAS—skin cancer	5.23e-06	0.000225	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—NRAS—skin cancer	5.2e-06	0.000224	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—TERT—skin cancer	5.19e-06	0.000223	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—TERT—skin cancer	5.1e-06	0.00022	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—TERT—skin cancer	5.09e-06	0.000219	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—NRAS—skin cancer	5.09e-06	0.000219	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—TERT—skin cancer	5.08e-06	0.000219	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—TERT—skin cancer	5.06e-06	0.000218	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—TERT—skin cancer	5.01e-06	0.000216	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—NRAS—skin cancer	4.98e-06	0.000214	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—NRAS—skin cancer	4.95e-06	0.000213	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—BRAF—skin cancer	4.89e-06	0.000211	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—BRAF—skin cancer	4.79e-06	0.000206	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—BRAF—skin cancer	4.68e-06	0.000201	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—BRAF—skin cancer	4.66e-06	0.0002	CbGpPWpGaD
Desipramine—CHRM4—Signaling by GPCR—HRAS—skin cancer	4.64e-06	0.0002	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—PTGS2—skin cancer	4.5e-06	0.000194	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—KRAS—skin cancer	4.48e-06	0.000193	CbGpPWpGaD
Desipramine—CHRM5—Signaling by GPCR—HRAS—skin cancer	4.44e-06	0.000191	CbGpPWpGaD
Desipramine—CHRM4—Signaling by GPCR—IL6—skin cancer	4.44e-06	0.000191	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.4e-06	0.00019	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—KRAS—skin cancer	4.38e-06	0.000189	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—NRAS—skin cancer	4.37e-06	0.000188	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—ENO2—skin cancer	4.35e-06	0.000187	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—NRAS—skin cancer	4.3e-06	0.000185	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—NRAS—skin cancer	4.29e-06	0.000185	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—KRAS—skin cancer	4.28e-06	0.000184	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—NRAS—skin cancer	4.28e-06	0.000184	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—NRAS—skin cancer	4.26e-06	0.000184	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—KRAS—skin cancer	4.26e-06	0.000184	CbGpPWpGaD
Desipramine—CHRM5—Signaling by GPCR—IL6—skin cancer	4.25e-06	0.000183	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—NRAS—skin cancer	4.22e-06	0.000182	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—ERCC2—skin cancer	4.2e-06	0.000181	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—PTGS2—skin cancer	4.19e-06	0.00018	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—PTGS2—skin cancer	4.13e-06	0.000178	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—BRAF—skin cancer	4.11e-06	0.000177	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—ERCC2—skin cancer	4.1e-06	0.000176	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—BRAF—skin cancer	4.04e-06	0.000174	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—BRAF—skin cancer	4.03e-06	0.000174	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—BRAF—skin cancer	4.02e-06	0.000173	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—BRAF—skin cancer	4.01e-06	0.000173	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—BRAF—skin cancer	3.97e-06	0.000171	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—PTGS2—skin cancer	3.87e-06	0.000167	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—ERCC2—skin cancer	3.86e-06	0.000166	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—HRAS—skin cancer	3.81e-06	0.000164	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—KRAS—skin cancer	3.76e-06	0.000162	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—NRAS—skin cancer	3.75e-06	0.000161	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—HRAS—skin cancer	3.72e-06	0.00016	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—KRAS—skin cancer	3.7e-06	0.000159	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—KRAS—skin cancer	3.69e-06	0.000159	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—KRAS—skin cancer	3.68e-06	0.000159	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—KRAS—skin cancer	3.67e-06	0.000158	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—IL6—skin cancer	3.64e-06	0.000157	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—HRAS—skin cancer	3.64e-06	0.000157	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—KRAS—skin cancer	3.63e-06	0.000156	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—HRAS—skin cancer	3.62e-06	0.000156	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—NRAS—skin cancer	3.59e-06	0.000155	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—IL6—skin cancer	3.56e-06	0.000153	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—IL6—skin cancer	3.49e-06	0.00015	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—IL6—skin cancer	3.47e-06	0.000149	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—PTGS2—skin cancer	3.33e-06	0.000143	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—ERCC2—skin cancer	3.27e-06	0.000141	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—PTGS2—skin cancer	3.26e-06	0.00014	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—KRAS—skin cancer	3.23e-06	0.000139	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—HRAS—skin cancer	3.2e-06	0.000138	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—HRAS—skin cancer	3.15e-06	0.000135	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—HRAS—skin cancer	3.14e-06	0.000135	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—HRAS—skin cancer	3.13e-06	0.000135	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—HRAS—skin cancer	3.12e-06	0.000134	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—HRAS—skin cancer	3.09e-06	0.000133	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—KRAS—skin cancer	3.09e-06	0.000133	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—NRAS—skin cancer	3.07e-06	0.000132	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—IL6—skin cancer	3.06e-06	0.000132	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—IL6—skin cancer	3.01e-06	0.00013	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—NRAS—skin cancer	3.01e-06	0.000129	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—IL6—skin cancer	3e-06	0.000129	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—IL6—skin cancer	3e-06	0.000129	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—IL6—skin cancer	2.99e-06	0.000129	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—IL6—skin cancer	2.96e-06	0.000127	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—NRAS—skin cancer	2.94e-06	0.000127	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—NRAS—skin cancer	2.93e-06	0.000126	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—TP53—skin cancer	2.87e-06	0.000123	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—TP53—skin cancer	2.75e-06	0.000118	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—HRAS—skin cancer	2.74e-06	0.000118	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—KRAS—skin cancer	2.65e-06	0.000114	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—HRAS—skin cancer	2.63e-06	0.000113	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—IL6—skin cancer	2.62e-06	0.000113	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—KRAS—skin cancer	2.59e-06	0.000111	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—NRAS—skin cancer	2.58e-06	0.000111	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—NRAS—skin cancer	2.54e-06	0.000109	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—NRAS—skin cancer	2.53e-06	0.000109	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—KRAS—skin cancer	2.53e-06	0.000109	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—NRAS—skin cancer	2.53e-06	0.000109	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—ERCC2—skin cancer	2.52e-06	0.000109	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—NRAS—skin cancer	2.52e-06	0.000108	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—KRAS—skin cancer	2.52e-06	0.000108	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PTGS2—skin cancer	2.52e-06	0.000108	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—IL6—skin cancer	2.51e-06	0.000108	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—NRAS—skin cancer	2.49e-06	0.000107	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PTGS2—skin cancer	2.46e-06	0.000106	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—TP53—skin cancer	2.35e-06	0.000101	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PTGS2—skin cancer	2.31e-06	9.97e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—TP53—skin cancer	2.3e-06	9.91e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—TP53—skin cancer	2.25e-06	9.69e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—HRAS—skin cancer	2.25e-06	9.68e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—TP53—skin cancer	2.24e-06	9.64e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—KRAS—skin cancer	2.22e-06	9.57e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—HRAS—skin cancer	2.2e-06	9.47e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—KRAS—skin cancer	2.19e-06	9.41e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—KRAS—skin cancer	2.18e-06	9.39e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—KRAS—skin cancer	2.17e-06	9.36e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—KRAS—skin cancer	2.17e-06	9.33e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—IL6—skin cancer	2.15e-06	9.27e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—HRAS—skin cancer	2.15e-06	9.26e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—KRAS—skin cancer	2.15e-06	9.24e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—HRAS—skin cancer	2.14e-06	9.22e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—IL6—skin cancer	2.11e-06	9.07e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—IL6—skin cancer	2.06e-06	8.87e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—IL6—skin cancer	2.05e-06	8.82e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—TP53—skin cancer	1.98e-06	8.5e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PTGS2—skin cancer	1.96e-06	8.44e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—TP53—skin cancer	1.94e-06	8.37e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—TP53—skin cancer	1.94e-06	8.35e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—TP53—skin cancer	1.93e-06	8.32e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—TP53—skin cancer	1.93e-06	8.3e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—TP53—skin cancer	1.91e-06	8.22e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—HRAS—skin cancer	1.89e-06	8.13e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—HRAS—skin cancer	1.86e-06	8e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—HRAS—skin cancer	1.85e-06	7.99e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—HRAS—skin cancer	1.85e-06	7.96e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—HRAS—skin cancer	1.84e-06	7.93e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—HRAS—skin cancer	1.82e-06	7.86e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—IL6—skin cancer	1.81e-06	7.78e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—IL6—skin cancer	1.78e-06	7.66e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—IL6—skin cancer	1.78e-06	7.64e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—IL6—skin cancer	1.77e-06	7.62e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—IL6—skin cancer	1.76e-06	7.59e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—IL6—skin cancer	1.75e-06	7.52e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PTGS2—skin cancer	1.51e-06	6.52e-05	CbGpPWpGaD
